UBS Group
RANI icon

UBS Group’s Rani Therapeutics RANI Stock Holding History

UBS Group’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Buy
297,270
+70,047
+31% +$62.1K ﹤0.01% 6722
2026
Q1 		$167K Buy
227,223
+75,700
+50% +$96.7K ﹤0.01% 6733
2025
Q4 		$205K Buy
151,523
+82,400
+119% +$124K ﹤0.01% 6565
2025
Q3 		$34.6K Buy
69,123
+7,059
+11% +$3.68K ﹤0.01% 7807
2025
Q2 		$31.9K Sell
62,064
-10,053
-14% -$8.2K ﹤0.01% 8117
2025
Q1 		$90.9K Buy
72,117
+48,592
+207% +$71.9K ﹤0.01% 7117
2024
Q4 		$32.2K Buy
23,525
+7,816
+50% +$16.4K ﹤0.01% 7555
2024
Q3 		$33.9K Buy
15,709
+12,709
+424% +$36.4K ﹤0.01% 7061
2024
Q2 		$11.4K Hold
3,000
– – ﹤0.01% 7644
2024
Q1 		$9.33K Buy
+3,000
New +$10.3K ﹤0.01% 7289
2023
Q4 		– Sell
-5,700
Closed -$12.4K – 9782
2023
Q3 		$12.4K Buy
5,700
+1,688
+42% +$6.45K ﹤0.01% 7021
2023
Q2 		$16.5K Buy
4,012
+3,012
+301% +$14K ﹤0.01% 6959
2023
Q1 		$5.16K Hold
1,000
– – ﹤0.01% 8076
2022
Q4 		$5.9K Hold
1,000
– – ﹤0.01% 9118
2022
Q3 		$10K Sell
1,000
-1,538
-61% -$16.3K ﹤0.01% 8451
2022
Q2 		$26K Sell
2,538
-1,032
-29% -$11.8K ﹤0.01% 6561
2022
Q1 		$48K Sell
3,570
-1,621
-31% -$26.9K ﹤0.01% 6537
2021
Q4 		$85K Buy
5,191
+2,121
+69% +$48.2K ﹤0.01% 6459
2021
Q3 		$55K Buy
+3,070
New +$53.1K ﹤0.01% 6265

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group's RANI Position: Q2 2026 in Review

UBS Group increased its Rani Therapeutics (RANI) stake by 31% in Q2 2026, buying an estimated $62.1K and bringing the position to 297,270 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #6722.

UBS Group first reported a position in RANI in Q3 2021 and has held it in 19 quarters since. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • UBS Group held 297,270 shares of Rani Therapeutics worth $226K as of Q2 2026.
  • UBS Group bought 70,047 Rani Therapeutics shares in Q2 2026, an estimated $62.1K.
  • Rani Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6722 holding.
  • UBS Group first reported a position in Rani Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.